Roche/Genentech spinal muscular atrophy treatment granted Orphan Drug designation

A monoclonal antibody under development from Roche (OTCQX:RHHBY) company Genentech was granted Orphan Drug designation for spinal muscular atrophy.
The treatment is classified as a recombinant humanized IgG1-based monoclonal antibody which binds to human latent myostatin in a pH dependent manner.
Genentech currently markets the spinal muscular atrophy treatment Evrysdi (risdiplam).
Roche inked a collaboration agreement earlier today with Recursion Pharmaceuticals (NASDAQ:RXRX) on neuroscience and oncology.